Operating Income (Loss) in USD of NGM BIOPHARMACEUTICALS INC from 2017 to Q4 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
NGM BIOPHARMACEUTICALS INC quarterly/annual Operating Income (Loss) history and change rate from 2017 to Q4 2023.
  • NGM BIOPHARMACEUTICALS INC Operating Income (Loss) for the quarter ending 31 Dec 2023 was -$29.7M, a 22.5% increase year-over-year.
  • NGM BIOPHARMACEUTICALS INC Operating Income (Loss) for the twelve months ending 31 Dec 2023 was -$151M, a 8.89% increase year-over-year.
  • NGM BIOPHARMACEUTICALS INC annual Operating Income (Loss) for 2023 was -$151M, a 8.89% increase from 2022.
  • NGM BIOPHARMACEUTICALS INC annual Operating Income (Loss) for 2022 was -$166M, a 37.7% decline from 2021.
  • NGM BIOPHARMACEUTICALS INC annual Operating Income (Loss) for 2021 was -$121M, a 16.2% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Change (%)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Change (%)

NGM BIOPHARMACEUTICALS INC Quarterly Operating Income (Loss) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q4 2023 -$151M -$29.7M +$8.63M +22.5% 01 Oct 2023 31 Dec 2023 10-K 11 Mar 2024
Q3 2023 -$160M -$31M +$17.3M +35.8% 01 Jul 2023 30 Sep 2023 10-Q 02 Nov 2023
Q2 2023 -$177M -$40.6M +$6.49M +13.8% 01 Apr 2023 30 Jun 2023 10-Q 03 Aug 2023
Q1 2023 -$184M -$50.2M -$17.6M -54.1% 01 Jan 2023 31 Mar 2023 10-Q 04 May 2023
Q4 2022 -$166M -$38.3M -$11.1M -40.7% 01 Oct 2022 31 Dec 2022 10-K 11 Mar 2024
Q3 2022 -$155M -$48.3M -$19.3M -66.5% 01 Jul 2022 30 Sep 2022 10-Q 02 Nov 2023
Q2 2022 -$136M -$47.1M -$10.4M -28.5% 01 Apr 2022 30 Jun 2022 10-Q 03 Aug 2023
Q1 2022 -$125M -$32.6M -$4.74M -17% 01 Jan 2022 31 Mar 2022 10-Q 04 May 2023
Q4 2021 -$121M -$27.2M +$449K +1.62% 01 Oct 2021 31 Dec 2021 10-K 11 Mar 2024
Q3 2021 -$121M -$29M +$951K +3.18% 01 Jul 2021 30 Sep 2021 10-Q 03 Nov 2022
Q2 2021 -$122M -$36.6M -$11.1M -43.4% 01 Apr 2021 30 Jun 2021 10-Q 04 Aug 2022
Q1 2021 -$111M -$27.8M -$7.18M -34.7% 01 Jan 2021 31 Mar 2021 10-Q 05 May 2022
Q4 2020 -$104M -$27.7M -$10.4M -60% 01 Oct 2020 31 Dec 2020 10-K 28 Feb 2023
Q3 2020 -$93.5M -$30M -$17M -130% 01 Jul 2020 30 Sep 2020 10-Q 04 Nov 2021
Q2 2020 -$76.5M -$25.5M -$15.8M -163% 01 Apr 2020 30 Jun 2020 10-Q 05 Aug 2021
Q1 2020 -$60.7M -$20.7M -$11.3M -121% 01 Jan 2020 31 Mar 2020 10-Q 06 May 2021
Q4 2019 -$49.3M -$17.3M -$30.4M -232% 01 Oct 2019 31 Dec 2019 10-K 17 Mar 2020
Q3 2019 -$19M -$13M -$4.53M -53.5% 01 Jul 2019 30 Sep 2019 10-Q 12 Nov 2020
Q2 2019 -$14.5M -$9.71M -$5.52M -132% 01 Apr 2019 30 Jun 2019 10-Q 12 Aug 2020
Q1 2019 -$8.94M -$9.34M -$4.63M -98.1% 01 Jan 2019 31 Mar 2019 10-Q 13 May 2020
Q4 2018 -$4.31M $13.1M 01 Oct 2018 31 Dec 2018 10-K 17 Mar 2020
Q3 2018 -$8.47M 01 Jul 2018 30 Sep 2018 10-K 17 Mar 2020
Q2 2018 -$4.19M 01 Apr 2018 30 Jun 2018 10-K 17 Mar 2020
Q1 2018 -$4.72M 01 Jan 2018 31 Mar 2018 10-K 17 Mar 2020

NGM BIOPHARMACEUTICALS INC Annual Operating Income (Loss) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$151M +$14.8M +8.89% 01 Jan 2023 31 Dec 2023 10-K 11 Mar 2024
2022 -$166M -$45.6M -37.7% 01 Jan 2022 31 Dec 2022 10-K 11 Mar 2024
2021 -$121M -$16.9M -16.2% 01 Jan 2021 31 Dec 2021 10-K 11 Mar 2024
2020 -$104M -$54.5M -110% 01 Jan 2020 31 Dec 2020 10-K 28 Feb 2023
2019 -$49.3M -$45M -1044% 01 Jan 2019 31 Dec 2019 10-K 01 Mar 2022
2018 -$4.31M +$13.1M +75.2% 01 Jan 2018 31 Dec 2018 10-K 15 Mar 2021
2017 -$17.4M 01 Jan 2017 31 Dec 2017 10-K 17 Mar 2020
* An asterisk sign (*) next to the value indicates that the value is likely invalid.